Niagen Bioscience, Inc.
NAGE
$3.17
$0.041.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.79M | 31.47M | 33.84M | 33.99M | 31.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.79M | 31.47M | 33.84M | 33.99M | 31.12M |
| Cost of Revenue | 10.47M | 11.50M | 12.14M | 12.06M | 10.89M |
| Gross Profit | 19.31M | 19.98M | 21.70M | 21.93M | 20.23M |
| SG&A Expenses | 17.10M | 16.92M | 17.89M | 15.90M | 15.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.09M | 29.90M | 31.74M | 29.75M | 27.93M |
| Operating Income | 700.00K | 1.58M | 2.10M | 4.24M | 3.19M |
| Income Before Tax | 1.07M | 6.74M | 4.42M | 4.80M | 3.74M |
| Income Tax Expenses | 106.00K | 417.00K | 292.00K | 222.00K | 128.00K |
| Earnings from Continuing Operations | 963.00K | 6.32M | 4.13M | 4.58M | 3.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 963.00K | 6.32M | 4.13M | 4.58M | 3.61M |
| EBIT | 700.00K | 1.58M | 2.10M | 4.24M | 3.19M |
| EBITDA | 991.00K | 1.87M | 2.30M | 4.43M | 3.38M |
| EPS Basic | 0.01 | 0.08 | 0.05 | 0.06 | 0.05 |
| Normalized Basic EPS | 0.01 | 0.02 | 0.02 | 0.04 | 0.03 |
| EPS Diluted | 0.01 | 0.07 | 0.05 | 0.05 | 0.04 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 |
| Average Basic Shares Outstanding | 79.32M | 79.92M | 78.97M | 79.78M | 79.25M |
| Average Diluted Shares Outstanding | 82.50M | 84.57M | 84.44M | 86.62M | 86.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |